Quanta Dialysis Technologies: QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer
QUANTA Appoints Dr Selwayan Saini as Chief Operating Officer
Alcester, Warwickshire, UK, 12 February 2021: QUANTA Dialysis Technologies Ltd ( QUANTA or the Company ), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of Dr Selwayan Saini as Chief Operating Officer with immediate effect.
Dr Saini brings with him over 15 years of experience working in senior operational roles in large global companies and in rapidly growing start-ups. Most recently he was Senior Director of Operations at Oxford Nanopore Technologies and prior to that he held various senior positions including CEO at Medtech Inside Biometrics and Vice President and Worldwide Director at Johnson & Johnson Medical Devices & Diagnostics. While at JNJ, he made significant contributions to chronic health management in the areas of dia
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE EU REGULATION 596/2014 ( MAR ) AND ARTICLE 7 OF MAR AS INCORPORATED INTO UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ( UK MAR ). MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN FARON PHARMACEUTICALS OY ( FARON ) PURSUANT TO THE PROPOSED TRANSACTION REFERRED TO IN THIS ANNOUNCEMENT. THIS ANNOUNCEMENT IS THEREFORE DIRECTED ONLY AT, IN A MEMBER STATE OF THE EUROPEAN ECONOMIC AREA, PERSONS WHO ARE QUALIFIED IN
gaitQ Provides Business Update
Support received from Parkinson s UK
Progress in user recruitment for clinical study
Oxford, UK, 9 February 2021 - gaitQ, a spin-out from the University of Oxford which is developing a wearable, smart medical device that helps those with Parkinson s overcome gait freezing episodes, is pleased to announce a business update on its recent and ongoing activities since launching in March 2020.
Funding
Since its inception in 2020, the company has made significant progress towards the development of the gaitQ system after attracting GBP 625,000 in pre-seed capital from both the University of Oxford Innovation Fund V, managed by Parkwalk Advisors, and via a private investment from Simon Godwin, recently appointed Chairman of gaitQ. Proceeds from the financing are being used to advance the early testing and development of gaitQ s device.
Immunocore Announces Pricing of Upsized Initial Public Offering
PRESS RELEASE
Immunocore Announces Pricing of Upsized Initial Public Offering
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896 American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. All ADSs sold in the offering were offered by Immunocore. The ADSs are expected to begin trading on The Nasdaq Global Select Market on February 5, 2021 under the ticker symbol “IMCR.” In addition, I